Agreement covers the co-development and co-commercialization of up to three T-cell therapies -Co-Development and Co-Commercialization Agreement • November 29th, 2022
- Astellas will pay Adaptimmune an upfront payment, research funding, development and commercial milestones, and royalties on net sales on co-commercialized products -
EX-10.28 3 dex1028.htm CO-COMMERCIALIZATION AGREEMENT [*] indicates that a confidential portion of the text of this agreement has been omitted. The non- public information has been filed separately with the Securities and Exchange Commission....Co-Development and Co-Commercialization Agreement • May 5th, 2020 • New York
This Co-Development and Co-Commercialization Agreement, dated as of December 17, 2003 (the “Effective Date”), is between XOMA (US) LLC, a Delaware limited liability company (“XOMA”), located at 2910 Seventh Street, Berkeley, CA 94710, and ALEXION PHARMACEUTICALS, INC., a Delaware corporation (“Alexion”), located at 352 Knotter Drive, Cheshire, CT 06410.
WITNESSETH:Co-Development and Co-Commercialization Agreement • January 9th, 2004 • Xoma LTD /De/ • Pharmaceutical preparations • New York
AMENDED AND RESTATED CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT FOR ERBITUX ® IN JAPANCo-Development and Co-Commercialization Agreement • February 29th, 2008 • Imclone Systems Inc • Biological products, (no disgnostic substances) • New York
THIS AMENDED AND RESTATED CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT FOR ERBITUX® IN JAPAN (this “Agreement”), effective as of October 12, 2007 (the “Restatement Effective Date”), is entered into by and among Bristol-Myers Squibb Company, a corporation organized and existing under the laws of the State of Delaware, having offices located at Route 206 & Province Line Road, Princeton, New Jersey (“Bristol”), E.R. Squibb & Sons, LLC, a limited liability company organized and existing under the laws of the State of Delaware, having offices located at Route 206 & Province Line Road, Princeton, New Jersey (“ERS”) (Bristol and ERS, collectively, “BMS”), Bristol-Myers K. K., a Japanese corporation, with its principal place of business at Shinjuku I-Land Tower, 5-1, Nishi-Shinjuku 6-chome, shinjuku-ku, Tokyo, 163-1328, Japan (“BMKK”), Merck KGaA, a German corporation with general partners organized and existing under the laws of the Federal Republic of Germany, having offices located at
ContractCo-Development and Co-Commercialization Agreement • March 11th, 2011
Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
WITNESSETH:Co-Development and Co-Commercialization Agreement • March 19th, 2004 • Xoma LTD /De/ • Pharmaceutical preparations • New York
IMCLONE LETTERHEAD] October 12, 2007Co-Development and Co-Commercialization Agreement • February 29th, 2008 • Imclone Systems Inc • Biological products, (no disgnostic substances) • New York
This letter agreement (this “Agreement”) is intended to clarify the rights and responsibilities of Merck KGaA, a German corporation with general partners (“Merck”), Merck Serono Japan Company, Limited, a Japanese corporation (“MJ”), and ImClone Systems Incorporated, a Delaware corporation (“ImClone”), under the Japan Agreement and under that certain Development and License Agreement, dated December 14, 1998, between Merck and ImClone (as such agreement has been amended, modified and supplemented, the “Existing Agreement”) with respect to Japan in light of their entry into the Japan Agreement. This Agreement shall become effective upon the signing of the Japan Agreement by all of the parties thereto (the “Effective Date”). Unless otherwise indicated, initially capitalized terms shall have the meanings given to them in the Japan Agreement.
CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENTCo-Development and Co-Commercialization Agreement • May 14th, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • New York
This CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT (this “Agreement”) is made as of 1 January 2018 (the “Effective Date”), by and between Arcturus Therapeutics, Inc., a Delaware corporation with offices at 10628 Science Center Drive, Suite 200, San Diego, California 92121, U.S. (“Arcturus”), and CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse 15, 72076 Tuebingen, Germany (“CureVac”). CureVac and Arcturus are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
